HTLV-2 infection in injection drug users in King County, Washington

References

• Feigal E, Murphy E, Vranizan K, Bacchetti P, Chaisson R, Drummond JE, et al. Human T-cell lymphotropic virus types I and II in intravenous drug users in San Francisco: risk factors associated with seropositivity. J Infect Dis 1991; 164: 36–42
   PubMedGoogle Scholar
• Khabbaz RF, Onorato IM, Cannon RO, Hartley TM, Roberts B, Hosein B, et al. Seroprevalence of HTLV-1 and HTLV-2 among intravenous drug users and persons in clinics for sexually transmitted diseases. N Engl J Med 1992; 326: 375–80
   PubMed Web of Science ®Google Scholar
• Schwebke J, Calsyn D, Shriver K, Saxon A, Kleyn J, Oluoch-Mitchell E, et al. Prevalence and epidemiologic correlates of human T-cell lymphotropic virus infection among intravenous drug users. J Infect Dis 1994; 169: 962–7
   PubMed Web of Science ®Google Scholar
• Thiede H, Harris NV, McGough JP, Roberts B, Khabbaz RF, Kaplan JE. Prevalence of HTLV types I and II among drug users in King County, Washington. West J Med 1994; 160: 540–4
   PubMedGoogle Scholar
• Dourado I, Andrade T, Carpenter CL, Galvao-Castro B. Risk factors for human T-cell lymphotropic virus type I among injecting drug users in north-east Brazil: possibly greater efficiency of male to female transmission. Mem Inst Oswaldo Cruz 1999; 94: 13–8
   PubMedGoogle Scholar
• Fuente LD, Toro C, Soriano V, Brugal MT, Vallejo F, Barrio G, et al. HTLV infection among young injection and non-injection heroin users in Spain: prevalence and correlates. J Clin Virol 2005; 35: 244–9
   PubMedGoogle Scholar
• Krook A, Albert J, Andersson S, Biberfeld G, Blomberg J, Eklund I, et al. Prevalence and risk factors for HTLV-II infection in 913 injecting drug users in Stockholm, 1994. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15: 381–6
   PubMedGoogle Scholar
• Vlahov D, Khabbaz RF, Cohn S, Galai N, Taylor E, Kaplan JE. Incidence and risk factors for human T-lymphotropic virus type II seroconversion among injecting drug users in Baltimore, Maryland, USA. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9: 89–96
   PubMedGoogle Scholar
• Maloney EM, Armien B, Gracia F, Castillo L, Kruger H, Levin A, et al. Risk factors for human T-cell lymphotropic virus type II infection among the Guaymi Indians of Panama. J Infect Dis 1999; 180: 876–9
   PubMedGoogle Scholar
• Murphy EL, Fridey J, Smith JW, Engstrom J, Sacher RA, Miller K, et al. HTLV-associated myelopathy in a cohort of HTLV-I and HTLV-II-infected blood donors. The REDS investigators. Neurology 1997; 48: 315–20
   PubMedGoogle Scholar
• Murphy EL, Glynn SA, Fridey J, Fridey J, Sacher RA, Smith JW, Wright DJ, et al. Increased prevalence of infectious diseases and other adverse outcomes in human T-lymphotropic virus types I- and II-infected blood donors. Retrovirus Epidemiology Donor Study (REDS) Study Group. J Infect Dis 1997; 176: 1468–75
   PubMed Web of Science ®Google Scholar
• Castillo LC, Gracia F, Roman GC, Levine P, Reeves WC, Kaplan J. Spinocerebellar syndrome in patients infected with human T-lymphotropic virus types I and II (HTLV-I/HTLV-II): report of 3 cases from Panama. Acta Neurol Scand 2000; 101: 405–12
   PubMed Web of Science ®Google Scholar
• Jacobson S, Lehky T, Nishimura M, Robinson S, McFarlin DE, Dhib-Jalbut S. Isolation of HTLV-II from a patient with chronic, progressive neurological disease clinically indistinguishable from HTLV-I-associated myelopathy/tropical spastic paraparesis. Ann Neurol 1993; 33: 392–6
   PubMedGoogle Scholar
• Harrington WJ, Jr, Sheremata W, Hjelle B, Dube DK, Bradshaw P, Foung SK, et al. Spastic ataxia associated with human T-cell lymphotropic virus type II infection. Ann Neurol 1993; 33: 411–4
   PubMed Web of Science ®Google Scholar
• Casoli C, Turci M, Pilotti E, Ciancianaini P, Bertazzoni U. Epidemiological and molecular data on 170 HTLV-II cases of Italian IDU. AIDS Res Hum Retrovirology 2003; 19: S7
   Google Scholar
• Visconti A, Visconti L, Bellocco R, Binkin N, Colucci G, Vernocchi L, et al. HTLV-II/HIV-1 coinfection and risk for progression to AIDS among intravenous drug users. J Acquir Immune Defic Syndr 1993; 6: 1228–37
   PubMedGoogle Scholar
• Hershow RC, Galai N, Fukuda K, Graber J, Vlahov D, Rezza G, et al. An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users. J Infect Dis 1996; 174: 309–17
   PubMedGoogle Scholar
• Bessinger R, Beilke MA, Kissinger P, Jarrott C, Tabak OF. Retroviral coinfections at a New Orleans HIV outpatient clinic. J Acquir Immune Defic Syndr 1997; 14: 67–71
   Google Scholar
• Harrison LH, Vaz B, Taveira DM, Quinn TC, Gibbs CJ, de Souza SH, et al. Myelopathy among Brazilians coinfected with human T-cell lymphotropic virus type I and HIV. Neurology 1997; 48: 13–8
   PubMedGoogle Scholar
• Toro C, Bassani S, Rios P, Jimenez V, Camino N, Soriano V. Influence of HTLV-2 infection on hepatitis C virus replication in HIV-positive patients. J Clin Virol 2005; 32: 338–9
   PubMedGoogle Scholar
• Hisada M, Chatterjee N, Zhang M, Battjes RJ, Goedert JJ. Increased hepatitis C virus load among injection drug users infected with human immunodeficiency virus and human T-lymphotropic virus type II. J Infect Dis 2003; 188: 891–7
   PubMed Web of Science ®Google Scholar
• Hagan H, Thiede H. Changes in injection risk behavior associated with participation in the Seattle needle-exchange program. J Urban Health 2000; 77: 369–82
   PubMed Web of Science ®Google Scholar
• Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol 1999; 149: 203–13
   PubMed Web of Science ®Google Scholar
• Schmid DS, Brown DR, Nisenbaum R, Burke RL, Alexander D, Ashley R, et al. Limits in reliability of glycoprotein G-based type-specific serologic assays for herpes simplex virus types 1 and 2. J Clin Microbiol 1999; 37: 376–9
   PubMedGoogle Scholar
• Hjelle B, Cyrus S, Swenson SG. Evidence for sexual transmission of human T- lymphotropic virus type II. Ann Intern Med 1992; 116: 90–1
   PubMedGoogle Scholar
• Roucoux DF, Wang B, Smith D, Nass CC, Smith J, Hutching ST, et al. A prospective study of sexual transmission of human T-lymphotropic virus (HTLV)-I and HTLV-II. J Infect Dis 2005; 191: 1490–7
   PubMed Web of Science ®Google Scholar
• Evans JL, Hahn JA, Page-Shafer K, Lum PJ, Stein ES, Davidson PJ, et al. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). J Urban Health 2003; 80: 137–46
   PubMed Web of Science ®Google Scholar
• Holmgren B, Andersson S, Harding E, Schim van der Loeff M, Vastrup P, Aaby P, et al. Increased prevalence of HTLV-1 among HIV-2-infected women but not HIV-2-infected men in rural Guinea-Bissau. J Acquir Immune Defic Syndr 2002; 30: 342–50
   PubMedGoogle Scholar
• Holmgren B, da Silva Z, Larsen O, Vastrup P, Andersson S, Aaby P. Dual infections with HIV-1, HIV-2 and HTLV-I are more common in older women than in men in Guinea-Bissau. Aids 2003; 17: 241–53
   PubMed Web of Science ®Google Scholar
• Henrard DR, Soriano V, Robertson E, Gutierrez M, Stephens J, Dronda F, et al. Prevalence of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 infection among Spanish drug users measured by HTLV-1 assay and HTLV-1 and -2 assay. HTLV-1 and HTLV-2 Spanish Study Group. J Clin Microbiol 1995; 33: 1735–8
   PubMedGoogle Scholar
• Soriano V, Vallejo A, Gutierrez M, Tuset C, Cilla G, Martinez-Zapico R, et al. Epidemiology of human T-lymphotropic virus type II (HTLV-II) infection in Spain. HTLV Spanish Study Group. Eur J Epidemiol 1996; 12: 625–9
   PubMed Web of Science ®Google Scholar
• Zunt JR, La Rosa A, Lama JR, Sanchez JL. HTLV-I and -II in high risk populations in Peru In: 53rd Annual Meeting of the American Society of Tropical Medicine and Hygiene, Miami, 2004.
   Google Scholar